Drugs / mRNA-1769
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05995275 | Aug 2023 → Jul 2025 | smallpox | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1769 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05995275 ↗ |
| Route | Intramuscular | “Participants will receive intramuscular (IM) injection of mRNA-1769 at Dose A on Day 1 and Day 29.” NCT05995275 ↗ |